Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
  • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
  • A61K47/38—Cellulose; Derivatives thereof
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
  • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
  • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

• the present invention relates to pharmaceutical formulations of N-(2-(2- (dimethylamino)ethoxy)-4-methoxy-5-((4-(l-methyl-lH-indol-3-yl)pyrimidin-2-yl)amino) phenyl) acryl amide, in particular methanesulfonic acid salt thereof, and methods of using the formulations for treating or preventing cancers.
• the epidermal growth factor receptor (EGFR, Herl, ErbBl) is a principal member of the ErbB family of four structurally-related cell surface receptors, with the other members being Her2 (Neu, ErbB2), Her3 (ErbB3), and Her4 (ErbB4).
• EGFR exerts its primary cellular functions through its intrinsic catalytic tyrosine protein kinase activity.
• the receptor is activated by binding with growth factor ligands, such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-a), which transform the catalytically inactive EGFR monomer into catalytically active homo- and hetero-dimers.
• growth factor ligands such as epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-a), which transform the catalytically inactive EGFR monomer into catalytically active homo- and hetero-dimers.
• EGFR is found at abnormally high levels on the surface of many types of cancer cells and increased levels of EGFR have been associated with advanced diseases, cancer spread, and poor clinical prognosis. Mutations in EGFR can lead to receptor overexpression, perpetual activation or sustained hyperactivity and result in uncontrolled cell growth, i.e., cancer. Consequently, EGFR mutations have been identified in several types of malignant tumors, including metastatic lung, head and neck, colorectal, and pancreatic cancers. In lung cancer, mutations mainly occur in exons 18 to 21, which encode the adenosine triphosphate (ATP)-binding pocket of the kinase domain.
• ATP adenosine triphosphate
• the most clinically relevant drug-sensitive EGFR mutations are deletions in exon 19 that eliminate a common amino acid motif (LREA) and point mutations in exon 21, which lead to a substitution of arginine for leucine at position 858 (L858R). Together, these two activating mutations account for nearly 85% of the EGFR mutations observed in lung cancer. Both mutations have perpetual tyrosine kinase activity and, as a result, they are oncogenic. In at least 50% of patients who are initially responsive to current therapy, disease progression is associated with the development of a secondary mutation, T790M in exon 20 of EGFR (referred to as the gatekeeper mutation). A need exists for the development of new effective and stable formulations for cancer treatment.
• the present invention provides pharmaceutical formulations of N-(2-(2- (dimethylamino)ethoxy)-4-methoxy-5-((4-(l-methyl-lH-indol-3-yl)pyrimidin-2- yl)amino)phenyl)acrylamide (compound 1), or a pharmaceutically acceptable salt thereof, with presence of pharmaceutically acceptable excipients, and methods of using the formulations for the treatment or prevention of diseases or medical conditions mediated through mutated forms of epidermal growth factor receptor (EGFR), such as various cancers.
• EGFR epidermal growth factor receptor
• the present invention provides a pharmaceutical formulation comprising a free base or, in a preferred embodiment, a mesylate salt (LMeSOsH, compound 2) of compound 1, as the active ingredient and one or more pharmaceutically acceptable excipients.
• a pharmaceutical formulation comprising a free base or, in a preferred embodiment, a mesylate salt (LMeSOsH, compound 2) of compound 1, as the active ingredient and one or more pharmaceutically acceptable excipients.
• compound 1 is in a crystalline form of mesylate salt, designated as Form 2A, having an X-ray powder diffraction pattern comprising the following 2 ⁇ values measured using CuKa radiation: 11.1° ⁇ 0.2°, 12.6° ⁇ 0.2°, 13.8° ⁇ 0.2°, 14.7° ⁇ 0.2°, 15.5° ⁇ 0.2°, 16.7° ⁇ 0.2°, 17.9° ⁇ 0.2°, 19.3° ⁇ 0.2°, 20.9° ⁇ 0.2°, 22.1° ⁇ 0.2°, 23.2° ⁇ 0.2°, 25.2° ⁇ 0.2°, and 25.8° ⁇ 0.2°.
• compound 1 is in a crystalline form of mesylate salt (compound 2), designated as Form 2B, having an X-ray powder diffraction pattern comprising the following 2 ⁇ values measured using CuKa radiation: 9.7° ⁇ 0.2°, 12.8° ⁇ 0.2°, 15.7° ⁇ 0.2°, 18.2° ⁇ 0.2°, 20.3° ⁇ 0.2°, 25.1° ⁇ 0.2°, 25.6° ⁇ 0.2°, and 26.8° ⁇ 0.2°.
• the pharmaceutically acceptable excipients contain one or more fillers selected from the group consisting of monohydrate lactose, anhydrous lactose, sucrose, dextrose, mannitol, sorbitol, starch, pregelatinized starch, microcrystalline cellulose, dihydrate or anhydrous dicalcium phosphate, calcium phosphate, calcium carbonate, and calcium sulfate, wherein each of said fillers is about 15% to about 50% of the formulation by weight.
• the pharmaceutically acceptable excipients contain one or more disintegrants selected from the group consisting of starch, pregelatinized starch, hydroxypropyl starch, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium, alginates, aluminum silicates, crospovidone, and hydroxypropyl cellulose, wherein each of said disintegrants is about 1% to about 10% of the formulation by weight.
• the pharmaceutically acceptable excipients contain one or more lubricants selected from the group consisting of magnesium stearate, calcium stearate, talc ("talcum powder”), polyethylene glycol (“PEG”), polymers of ethylene oxide, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, and silicon dioxide, wherein each of said lubricants is about 1% to about 10% of the formulation by weight.
• talc talcum powder
• PEG polyethylene glycol
• lubricants selected from the group consisting of magnesium stearate, calcium stearate, talc (“talcum powder”), polyethylene glycol (“PEG”), polymers of ethylene oxide, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, and silicon dioxide, wherein each of said lubricants is about 1% to about 10% of the formulation by weight.
• the pharmaceutically acceptable excipients contain one or more binders selected from the group consisting of acacia, cellulose derivatives (e.g. : methylcellulose, carboxymethylcellulose, hydroxypropylm ethyl cellulose, hydroxypropylcellulose, hydroxyethylcellulose), gelatin, glucose, dextrose, xylitol, polymethacrylates, polyvinylpyrrolidone, sorbitol, starch, tragacanth, xanthane resin, alginates, magnesium-aluminum silicate, polyethylene glycol (PEG), and bentonite, wherein each of said binders is about 5% to about 30% of the formulation by weight.
• binders selected from the group consisting of acacia, cellulose derivatives (e.g. : methylcellulose, carboxymethylcellulose, hydroxypropylm ethyl cellulose, hydroxypropylcellulose, hydroxyethylcellulose), gelatin, glucose, dextrose
• Another aspect of the invention provides a method of treating a disease or disorder associated with an EGFR activity, comprising administration of a therapeutically effective amount of a formulation described herein to a patient in need thereof.
• the disease or disorder is associated with one or more mutants of EGFR.
• the mutant or mutants of EGFR are selected from L858R activating mutants L858R, delE746-A750, G719S; the Exon 19 deletion activating mutant; and the T790M resistance mutant.
• the disease or disorder is a cancer.
• Another aspect of the invention provides use of pharmaceutical compositions comprising methanesulfonic acid salt of compound 1 in the manufacture of medicaments for treatment of diseases or conditions, in particular various cancers, related to one or more mutants of EGFR.
• FIG. 1A and IB illustrate the XRPD pattern and XRPD data, respectively, of lJVIeSOsH (compound 2) in crystalline Form 2A.
• FIG. 2 illustrates DSC thermogram of compound 2 (Form 2A).
• FIG. 3 illustrates TGA thermogram of compound 2 (Form 2A).
• FIG. 4 A and 4B illustrate the XRPD pattern and XRPD data, respectively, of compound 2 in crystalline Form 2B.
• FIG. 5 illustrates a TGA-MS thermogram of compound 2 (Form 2A).
• FIG. 6 illustrates a DSC thermogram of compound 2 (Form 2B).
• FIG. 7 illustrates the overlay of HPLC chromatograms of compound 2 as control in the stability testing of Formulation 1 at 50 °C.
• FIG. 8 illustrates the overlay of HPLC chromatograms from stability testing of Formulation 1 at 50 °C.
• FIG. 9 illustrates the overlay of HPLC chromatograms from stability testing of Formulation 1 at 40 °C @ 75% relative humidity.
• Compound 1 effectively inhibits the kinase domain of the T790M double mutant in addition to the activating mutations and therefore overcomes the resistance observed with the currently used therapy of reversible inhibitors. Since the role of EGFR in non-small cell lung cancer (NSCLC) is well-established, compound 1 represents a novel therapeutic agent for the treatment of non-small cell lu
• the present invention provides a pharmaceutically acceptable salt of the compound 1 and a formulation of compound 1 or a pharmaceutically acceptable salt thereof.
• the formulation not only ensures a desirable pharmacokinetics profile but also demonstrates excellent stability over an extended period.
• the term "pharmaceutically acceptable excipient or carrier” refers to any substance, not itself a therapeutic agent, used as a carrier, diluent, adjuvant, binder, lubricant, disintegrant and/or vehicle for delivery of a therapeutic agent to a patient, or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a compound or pharmaceutical composition into a unit dosage form for administration.
• Pharmaceutically acceptable excipients are known in the pharmaceutical arts and are disclosed, for example, in Remington: The Science and Practice of Pharmacy, 21 st Ed.
• pharmaceutically acceptable excipients can provide a variety of functions and can be described as wetting agents, buffering agents, suspending agents, lubricating agents, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavorants, and sweeteners, or the like.
• the term "subject” or “patient” refers to a mammal, including but not limited to, a human. Hence, the methods disclosed herein can be useful in human therapy and veterinary applications.
• the patient is a mammal.
• the patient is a human.
• the patient is a mammalian animal such as dogs, cats, and horses.
• the articles “a” and “an” as used herein refers to “one or more” or “at least one,” unless otherwise indicated. That is, reference to any element or component of the present invention by the indefinite article “a” or “an” does not exclude the possibility that more than one element or component is present.
• treating refers to: (i) inhibiting the disease, disorder, or condition, i.e., arresting its development; or (ii) relieving the disease, disorder, or condition, i.e., causing regression of the disease, disorder, and/or condition.
• “treating” or “treatment” refers to ameliorating a disease or disorder, which may include ameliorating one or more physical parameters, though maybe indiscernible by the subject being treated.
• “treating" or “treatment” includes modulating the disease or disorder, either physically (e.g., stabilization of a discernible symptom) or physiologically (e.g., stabilization of a physical parameter) or both.
• An aspect of the invention provides pharmaceutical formulations comprising compound 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.
• the active ingredient compound 1 is in a free base form in the formulation.
• the active ingredient is a pharmaceutically acceptable salt of compound 1.
• the acid suitable for forming the salt include methanesulfonic acid, hydrochloride acid, sulfuric acid, toluenesulfonic acid, and citric acid.
• the amount of compound 1 or a pharmaceutically acceptable salt thereof in the formulation depends on factors such as the target treatment, the administration regimen, and the actual excipients.
• exemplary ranges for compound 1 or a pharmaceutically acceptable salt thereof in the formulation include about 10% to about 50%, about 10%> to about 30%), about 15%> to about 35%, about 15%> to about 30%>, and about 15%> and about 25% by weight.
• the active ingredient in the formulation is a mesylate salt of compound 1 (i.e., the compound 2).
• the present invention provides a pharmaceutical formulation comprising a crystalline form of mesylate salt designated as Form 2A, having an X-ray powder diffraction pattern comprising the following 2 ⁇ values measured using CuKa radiation: 12.6° ⁇ 0.2°, 15.5° ⁇ 0.2°, 17.9° ⁇ 0.2°, 22.1° ⁇ 0.2°, and 25.2° ⁇ 0.2°.
• the crystalline Form 2A has one or more of the following characteristics: (a) the X-ray powder diffraction pattern containing two or more of the following 2 ⁇ values measured using CuKa radiation: 11.1° ⁇ 0.2°, 13.8° ⁇ 0.2°, 14.7° ⁇ 0.2°, 16.7° ⁇ 0.2°, 19.3° ⁇ 0.2°, 20.9° ⁇ 0.2°, 23.2° ⁇ 0.2°, and 25.8° ⁇ 0.2°;
• thermogram substantially as depicted in FIG. 2;
• the present invention provides a pharmaceutical formulation comprising a crystalline form of mesylate salt designated as Form 2B, characterized by having one or more of the following characteristics:
• thermogram substantially as depicted in FIG. 6;
• FIG. 5 is a diagrammatic representation of FIG. 5.
• the formulation of the present invention includes one or more pharmaceutically acceptable excipients.
• excipients include filler, binder, disintegrant, lubricant, surfactant, pH modifier or any combination from these.
• the excipients comprise one or more members selected from filler, binder, disintegrant, and lubricant.
• the amount of the excipient or excipients in the formulation ranges from about 10% to about 98%, all subranges included, by weight. Examples of the amount of the excipient or excipients include about 1%, about 5%, about 10%, about 15%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, and about 95% by weight.
• Suitable fillers include, but are not limited to, monohydrate lactose, anhydrous lactose, sucrose, dextrose, mannitol, sorbitol, starch, pregelatinized starch, cellulose (particularly microcrystalline cellulose), dihydrate or anhydrous dicalcium phosphate, calcium phosphate, calcium carbonate, and calcium sulfate.
• Each filler accounts for from about 15% to about 70%, from about 15% to about 60%, from about 15% to about 50%, from about 20%) to about 60%, or from about 20% to about 50% of the formulation by weight.
• the fillers comprise microcrystalline cellulose as a first filler and a second filler selected from the group consisting of monohydrate lactose, anhydrous lactose, sucrose, dextrose, mannitol, sorbitol, starch, pregelatinized starch, dihydrate or anhydrous dicalcium phosphate, calcium phosphate, calcium carbonate, and calcium sulfate.
• Suitable binders include, but are not limited to, acacia, cellulose derivatives (e.g. methylcellulose, carboxymethylcellulose, hydroxypropylmethyl cellulose, hydroxypropylcellulose, hydroxyethylcellulose), gelatin, glucose, dextrose, xylitol, polymethacrylates, polyvinylpyrrolidone, sorbitol, starch, tragacanth, xanthane resin, alginates, magnesium-aluminum silicate, polyethylene glycol (PEG), and bentonite.
• Each binder accounts for from about 1% to about 50%, from about 5% to about 50%, from about 10%) to about 50%), from about 5% to about 30%, or from about 5% to about 20% of the formulation by weight.
• Suitable disintegrants include, but are not limited to, starch, pregelatinized starch, hydroxypropyl starch, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium, alginates, aluminum silicates, crospovidone, and low- substituted hydroxypropyl cellulose.
• Each disintegrant accounts for from about 1% to about 10%, from about 1%) to about 7%, from about 1% to about 5%, or from about 2% to about 4% of the formulation by weight.
• the disintegrant consists of one, two, three, or four members selected from starch, pregelatinized starch, hydroxypropyl starch, sodium starch glycolate, sodium carboxymethylcellulose, croscarmellose sodium, alginates, aluminum silicates, crospovidone, and low- substituted hydroxypropyl cellulose.
• Suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, talc ("talcum powder”), polyethylene glycol ("PEG”), polymers of ethylene oxide, sodium lauryl sulfate, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, and silicon dioxide. Each lubricant accounts for from about 1% to about 10%, from about 1% to about 7%), from about 1% to about 5%, or from about 2% to about 4% of the formulation by weight.
• the lubricant consists of one, two, three, or four members selected from magnesium stearate, calcium stearate, talc ("talcum powder"), polyethylene glycol ("PEG”), polymers of ethylene oxide, magnesium lauryl sulfate, sodium oleate, sodium stearyl fumarate, and silicon dioxide.
• the formulation is substantially free from sodium lauryl sulfate.
• the pharmaceutically acceptable excipients in the formulation comprise microcrystalline cellulose, dicalcium phosphate, sodium starch glycolate, silicon dioxide, and magnesium stearate.
• the pharmaceutically acceptable excipients in the formulation consist substantially of microcrystalline cellulose, dicalcium phosphate, sodium starch glycolate, silicon dioxide, and magnesium stearate.
• a specific example of the formulation of this type is the Formulation 1 substantially described in Example 3 and Table 1.
• the pharmaceutically acceptable excipients in the formulation comprise microcrystalline cellulose, lactose monohydrate, sodium lauryl sulfate, croscarmellose sodium, silicon dioxide, and magnesium stearate.
• the pharmaceutically acceptable excipients in the formulation consist substantially of microcrystalline cellulose, lactose monohydrate, sodium lauryl sulfate, croscarmellose sodium, silicon dioxide, and magnesium stearate.
• a specific example of the formulation of this type is the Formulation 2 substantially described in Example 4 and Table 2.
• Examples of the dosage form of the present invention include a capsule, a tablet, sachet, or granule powder.
• a unit dosage form contains, for example, about 1 mg to about 1000 mg of compound 1 or a pharmaceutically acceptable salt thereof.
• Non-limiting examples of the amount of compound 1 or a pharmaceutically acceptable salt thereof in the unit dosage form include about 1 mg, about 5 mg, about 7.5 mg, about 10 mg, about 25 mg, about 35 mg, about 40, or about 50 mg.
• a dosage form may contain one or more unit dosage forms.
• methanesulfonic acid salt As used herein, the terms “methanesulfonic acid salt”, “methanesulfonate salt”, “mesylate salt”, or the like are used interchangeably. They refer to an acid addition salt having a general formula l.MeS0 3 H i.e., compound 2. Preferably, the salt contains compound 1 and methanesulfonic acid in 1 : 1 mole ratio, or substantially in 1 : 1 mole ratio.
• the ratio may or may not be exactly 1 : 1; therefore, an addition salt of this type having a ratio between 1 and MeS0 3 H in the range of 1 :0.8 to 1 : 1.2 should be considered a salt of l.MeS0 3 H, which is preferably controlled within 1 :0.9 to 1 : 1.1, and more preferably within 1 :0.95 to 1 :05 ratio.
• l.MeS0 3 H which is preferably controlled within 1 :0.9 to 1 : 1.1, and more preferably within 1 :0.95 to 1 :05 ratio.
• co-presence of compound 1 and methanesulfonic acid in any ratio would likely form a mesylate salt, i.e. compound 2, though depending on the ratio, either compound 1 or the acid may partially exist as a free base or free acid, respectively.
• the mesylate salt of compound 1, depending on crystalline forms and the solvents from which it is generated, may be in the form of a solvate, i.e., containing a varying amount of solvent molecules, such as water (hydrate), methanol, THF, or the like. All of these salt forms or solvate forms may be formulated substantially using the methods disclosed herein, and they are all encompassed by the present invention.
• the present invention provides a method of treating a disease or disorder associated with an EGFR activity, the method comprising administration of a pharmaceutical formulation comprising a methanesulfonic acid salt of compound 1 according to any embodiments disclosed herein to a subject in need thereof.
• the disease or disorder is associated with one or more mutants of EGFR.
• the mutant or mutants of EGFR are selected from L858R activating mutants L858R, delE746-A750, G719S; the Exon 19 deletion activating mutant; and the T790M resistance mutant.
• the disease or disorder is a cancer.
• the cancer is selected from brain cancer, lung cancer, kidney cancer, bone cancer, liver cancer, bladder cancer, head and neck cancer, esophageal cancer, stomach cancer, colon cancer, rectum cancer, breast cancer, ovarian cancer, melanoma, skin cancer, adrenal cancer, cervical cancer, lymphoma, and thyroid tumors, or their complications.
• the cancer is brain cancer or lung cancer.
• the cancer is a metastatic brain cancer.
• the compound 1 can be used for treatment of brain cancers, including metastatic brain cancer.
• the formulations of present invention are particularly useful for treatment of patients with these conditions.
• Particular useful formulations for these therapeutic uses include the Formulation 1 and Formulation 2 disclosed herein.
• any embodiment of the method of treating diseases or disorders is used in combination with administering to the patient a second therapeutic agent.
• the second therapeutic agent is a chemotherapeutic agent. In some embodiments, the second therapeutic agent is a different EGFR modulator. In another aspect, the present invention provides a method of inhibiting a mutant of EGFR in a subject, comprising contacting a biological sample of a patient with a formulation according to any embodiments disclosed herein.
• the present invention provides use of a formulation according to any embodiments disclosed herein in the manufacture of a medicament for treatment of a disease or disorder associated with an EGFR activity.
• the disease or disorder is a cancer selected from the group consisting of brain cancer, lung cancer, kidney cancer, bone cancer, liver cancer, bladder cancer, head and neck cancer, esophageal cancer, stomach cancer, colon cancer, rectum cancer, breast cancer, ovarian cancer, melanoma, skin cancer, adrenal cancer, cervical cancer, lymphoma, and thyroid tumors and their complications.
• the disease or disorder is brain cancer or lung cancer.
• the formulation of present invention may be used for delaying the onset of the disease or disorder or preventing a disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder, and/or condition but has not yet been diagnosed as having it.
• Another aspect of the present invention provides methods processes of preparing formulations according to any embodiments disclosed herein as substantially described and shown.
• compositions may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose.
• the pharmaceutical formulations of this disclosure will be administered from about 1 to about 5 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy.
• the amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending on the condition being treated, the severity of the condition, the time of administration, the route of administration, the rate of excretion of the compound employed, the duration of treatment, and the age, gender, weight, and condition of the patient.
• Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient.
• treatment is initiated with small dosages substantially less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect under the circumstances is reached.
• the compound is most desirably administered at a concentration level that will generally afford effective results without causing substantial harmful or deleterious side effects.
• both the compound 1 and the additional agent are usually present at dosage levels of between about 10 to 150%, and more preferably between about 10 and 80% of the dosage normally administered in a monotherapy regimen.
• compositions may be adapted for administration by any appropriate route, for example, by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual, or transdermal), vaginal, or parenteral (including subcutaneous, intracutaneous, intramuscular, intra-articular, intrasynovial, intrasternal, intrathecal, intralesional, intravenous, or intradermal injections or infusions) route.
• Such formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s). Oral administration or administration by injection is preferred.
• compositions adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil emulsions.
• the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
• an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
• Powders are prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for example, starch or mannitol. Flavoring, preservative, dispersing, and coloring agent can also be present.
• Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths.
• Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate, or solid polyethylene glycol can be added to the powder mixture before the filling operation.
• a disintegrating or solubilizing agent such as agar-agar, calcium carbonate, or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.
• Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant, and pressing into tablets.
• a powder mixture is prepared, for example, by mixing the compound, suitable comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginate, gelating, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or and absorption agent such as betonite, kaolin, or dicalcium phosphate.
• a binder such as carboxymethylcellulose, an aliginate, gelating, or polyvinyl pyrrolidone
• a solution retardant such as paraffin
• a resorption accelerator such as a quaternary salt and/or
• absorption agent such as betonite, kaolin, or dicalcium phosphate.
• the powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or polymeric materials and forcing through a screen.
• a binder such as syrup, starch paste, acadia mucilage, or solutions of cellulosic or polymeric materials and forcing through a screen.
• the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules.
• the granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc, or mineral oil.
• the lubricated mixture is then compressed into tablets.
• the compounds of the present disclosure can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging steps.
• a clear or opaque protective coating consisting of a sealing coat of shellac,
• dosage unit formulations for oral administration can be microencapsulated.
• the formulation can also be prepared to prolong or sustain the release as for example by coating or embedding particulate material in polymers, wax, or the like.
• Step 1 A solution of 4-(2-(dimethylamino)ethoxy)-6-methoxy-N-l-(4-(l-methyl-lH- indol-3-yl)pyrimidin-2-yl)benzene-l,3 diamine (A, prepared as in International Application No. PCT/US 15/65286; 1 equiv, 16.8 g, 26.2 mmol) in THF (550 mL) and water (120 mL) was cooled to 0-5 °C. Acryloyl chloride (1.0 equiv., 3.3 mL) was added dropwise over 30 minutes.
• Step 2 To a solution of compound 1, prepared as in Step 1, (1 eq, 22.5 g, 46.3 mmol), in 850 mL of THF was added NaOH (9 g dissolved in 203 mL of H 2 0) over 5 min. The mixture was heated to 60 °C with stirring for 50 min, then cooled to 10-20°C and IN HC1 (180 mL) was added over 20 min. The layers were separated and the aqueous phase was extracted with dichloromethane (2 X 400 mL). The organic phases were combined, dried (Na 2 S0 4 ) and concentrated.
• Form 2A is a beige crystalline powder; and its XRPD pattern is shown in FIG. 1. It shows birefringence and has a melting point with onset temperature at 233.3 °C, -0.40% weight loss before the melting point in the differential scanning calorimetry (DSC) analysis (FIG. 2) and -0.035% weight loss from 170 °C to 210 °C in the thermogravimetric analysis (TGA) (FIG. 3).
• DSC differential scanning calorimetry
• TGA thermogravimetric analysis
• Form 2A A polymorph screening study was performed on Form 2A by the slurry, solvent- thermal heating/cooling, anti-solvent precipitation, solid heating-cooling and grinding methods.
• One new crystal form, Form 2B was obtained by precipitation from an aqueous solution using dioxane as antisolvent at room temperature.
• Form 2B may be a hydrate form of Form 2A and shows lower crystallinity, lower melting point and higher weight loss as compared with the Form 2A.
• XRPD, TGA-MS, and DSC analyses of Form 2B are shown in FIGs. 4, 5, and 6, respectively. Because of its apparent superior stability, while not intended to be limiting, crystalline Form 2A has been used for preparing formulations of the methanesulfonate salt (compound 2) in this application.
• Microcrystalline cellulose (392.43 mg), dicalcium phosphate (735.35 mg), sodium starch glycolate (45.09 mg), silicon dioxide (15.03 mg), and magnesium stearate (15.03 mg) were combined and blended with a vortex mixer in the amounts and proportions indicated in Table 1.
• the resulting mixture was filtered through a #35 mesh sieve to give Mixture A.
• a 20.05 mg portion of Mixture A was combined with 5.0 mg of l Ms (C 27 H 30 N 6 O 3 - 1.06
• Formulation 2 of compound 2 was prepared and analyzed by substantially similar procedures as described above. Microcrystalline cellulose (545.23 mg), lactose monohydrate (495.71 mg), sodium lauryl sulfate (7.51 mg), croscarmellose sodium (42.58 mg), silicon dioxide (14.19 mg), and magnesium stearate (14.19 mg) were combined and blended with a vortex mixer in the amounts and proportions indicated in Table 1. Crystalline Form 2A was used in the preparation of all samples in this example. The resulting mixture was filtered through a #35 mesh sieve to give Mixture B.
• Formulation 1 100.0 0.00 101.4 0.00 99.9 0.00 100.7 0.00 100.2 0.00
• TRS total related substances.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (16)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=64660336

Family Applications (1)

Country Status (16)

Cited By (4)

Citations (7)

Family Cites Families (8)

• 2018
  • 2018-06-15 SG SG11201911859QA patent/SG11201911859QA/en unknown
  • 2018-06-15 KR KR1020207000966A patent/KR20200016969A/ko not_active Application Discontinuation
  • 2018-06-15 JP JP2019569270A patent/JP7045726B2/ja active Active
  • 2018-06-15 CA CA3067044A patent/CA3067044A1/en not_active Abandoned
  • 2018-06-15 MX MX2019015177A patent/MX2019015177A/es unknown
  • 2018-06-15 AU AU2018283289A patent/AU2018283289B2/en active Active
  • 2018-06-15 TW TW107120801A patent/TW201904577A/zh unknown
  • 2018-06-15 EA EA201992744A patent/EA201992744A1/ru unknown
  • 2018-06-15 US US16/622,119 patent/US11180478B2/en active Active
  • 2018-06-15 CN CN201880040172.8A patent/CN110799191B/zh active Active
  • 2018-06-15 WO PCT/US2018/037744 patent/WO2018232235A1/en active Application Filing
  • 2018-06-15 EP EP18817811.5A patent/EP3638241B1/en active Active
  • 2018-06-15 BR BR112019026483-3A patent/BR112019026483A2/pt not_active Application Discontinuation
• 2019
  • 2019-12-05 IL IL271220A patent/IL271220A/en unknown
  • 2019-12-16 PH PH12019502830A patent/PH12019502830A1/en unknown
  • 2019-12-18 CO CONC2019/0014350A patent/CO2019014350A2/es unknown
• 2021
  • 2021-11-12 US US17/524,866 patent/US20220153726A1/en active Pending
• 2022
  • 2022-01-05 JP JP2022000480A patent/JP2022058492A/ja active Pending

Patent Citations (7)

Also Published As

Similar Documents

Legal Events